Bausch Health Companies Inc (BHC)

Currency in USD
8.35
+0.21(+2.52%)
Real-time Data·
BHC is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
8.238.40
52 wk Range
4.339.04
Key Statistics
Prev. Close
8.14
Open
8.36
Day's Range
8.23-8.4
52 wk Range
4.33-9.04
Volume
945.76K
Average Volume (3m)
3.29M
1-Year Change
23.8872%
Book Value / Share
-3.55
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BHC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
8.00
Downside
-4.19%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

0 Buy
7 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 8.00
(-4.19% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Jefferies
Hold8.00-4.19%6.50MaintainOct 29, 2026
RBC Capital
Hold10.00+19.76%9.00MaintainOct 29, 2026
RBC Capital
Hold9.00+7.78%-MaintainOct 08, 2026
RBC Capital
Hold9.00+7.78%10.00MaintainApr 27, 2026
Barclays
Hold7.00-16.17%8.00MaintainFeb 25, 2026

Bausch Health Companies Inc SWOT Analysis


Financial Resilience
Bausch Health's Q3 2024 results showcase robust growth, with revenues of $2.51 billion marking a 12% year-over-year increase and 9% organic growth
Debt Dilemma
Explore the complexities of Bausch Health's $21.5 billion debt burden and its impact on strategic initiatives, including potential bankruptcy concerns
Strategic Crossroads
Delve into Bausch Health's plans for asset separation, particularly the Bausch+Lomb division, and how debt issues may affect these crucial moves
Market Sentiment
Analysts offer mixed views, with price targets ranging from $8 to $11, reflecting the tension between strong performance and financial challenges
Read full SWOT analysis

Bausch Health Companies Inc Earnings Call Summary for Q3/2026

  • Bausch Health beat Q3 estimates with EPS of $1.77 vs. $1.27 forecast and revenue of $2.94B vs. $2.75B; shares surged 9.67% to $6.92, then 13.15% after-hours.
  • Adjusted EBITDA rose 32% to $1.305B while cash flow from operations jumped 54% to $782M; net debt reduced by $521M in the quarter to strengthen balance sheet.
  • Company raised full-year 2026 guidance for second consecutive quarter: revenue midpoint up $150M, EBITDA up $190M, and cash flow up $200M from prior outlook.
  • Management flagged $400M-$500M XIFAXAN revenue headwind for 2027 from Medicare pricing and IRA changes, with gross-to-net accrual adjustment exceeding $100M.
  • CEO Appio highlighted 14 consecutive quarters of revenue and EBITDA growth ex-Bausch + Lomb; larsucosterol remains on track for potential 2029 approval target.
Last Updated: 10/29/2026, 05:50 AM
Read Full Transcript

Earnings

Latest Release
Oct 28, 2026
EPS / Forecast
1.77 / 1.27
Revenue / Forecast
2.94B / 2.75B
EPS Revisions
Last 90 days

BHC Income Statement

Compare BHC to Peers and Sector

Metrics to compare
BHC
Peers
Sector
Relationship
P/E Ratio
−3.7x6.0x−0.3x
PEG Ratio
0.01−0.330.00
Price/Book
−2.4x1.6x2.6x
Price / LTM Sales
0.3x1.9x2.8x
Upside (Analyst Target)
−3.0%9.1%67.2%
Fair Value Upside
Unlock13.3%10.1%Unlock

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, Czech Republic, Slovakia, Ukraine, Bulgaria, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Employees
20300

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
44.10M11.79%353.64M
Other Institutional Investors
230.08M61.52%1.85B
Public Companies & Retail Investors
99.82M26.69%800.55M
Total
373.99M100.00%3B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Paulson & Co. Inc.19.59%73,255,869587,512
GoldenTree Asset Management LP9.27%34,665,731278,019

People Also Watch

13.86
OGN
+0.04%
17.61
KD
+36.09%
91.93
ACLS
-5.60%
48.68
PENG
-8.48%
136.65
CHRD
-4.99%

FAQ

What Is the Bausch Health (BHC) Stock Price Today?

The Bausch Health stock price today is 8.35 USD.

What Stock Exchange Does Bausch Health Trade On?

Bausch Health is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Bausch Health?

The stock symbol for Bausch Health is "BHC."

What Is the Bausch Health Market Cap?

As of today, Bausch Health market cap is 3.13B USD.

What Is Bausch Health's Earnings Per Share (TTM)?

The Bausch Health EPS (TTM) is -2.25.

When Is the Next Bausch Health Earnings Date?

Bausch Health will release its next earnings report on Feb 24, 2027.

From a Technical Analysis Perspective, Is BHC a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Bausch Health Stock Split?

Bausch Health has split 2 times.

How Many Employees Does Bausch Health Have?

Bausch Health has 20300 employees.

What is the current trading status of Bausch Health (BHC)?

As of Nov 04, 2026, Bausch Health (BHC) is trading at a price of 8.35 USD, with a previous close of 8.14 USD. The stock has fluctuated within a day range of 8.23 USD to 8.40 USD, while its 52-week range spans from 4.33 USD to 9.04 USD.

What Is Bausch Health (BHC) Price Target According to Analysts?

The average 12-month price target for Bausch Health is 8.00 USD, with a high estimate of 10 USD and a low estimate of 7 USD. 0 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Neutral. The stock has an -4.19% Downside potential.

What Is the BHC Premarket Price?

BHC's last pre-market stock price is 8.30 USD. The pre-market share volume is 6,420.00, and the stock has decreased by 0.16, or 1.97%.

What Is the BHC After Hours Price?

BHC's last after hours stock price is 8.23 USD, the stock has decreased by 0.09, or 1.07%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.